Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
Identifieur interne : 004374 ( Main/Exploration ); précédent : 004373; suivant : 004375Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
Auteurs : Maria C. Obinu [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Assunta Imperato [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-01.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Adult animal, Animals, Behavior, Animal (drug effects), Benzothiazole, Callithrix, Chemotherapy, Disease Models, Animal, Dopamine (metabolism), Dopamine Agents (adverse effects), Dopaminergic neuron, Female, Immunohistochemistry, Locomotion (drug effects), MPTP, Male, Monkey, Motricity, Neuroprotective Agents (pharmacology), Neuroprotective Agents (therapeutic use), Neuroprotective agent, Nissl Bodies (drug effects), Nissl Bodies (metabolism), Nissl Bodies (pathology), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson disease, Pathology, Prognosis, Psychotropic, Random Allocation, Riluzole, Riluzole (pharmacology), Riluzole (therapeutic use), Substantia Nigra (drug effects), Treatment, locomotor impairment, neurological deficit, neuronal loss, neuroprotection, riluzole.
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Dopamine Agents.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Behavior, Animal, Locomotion, Nissl Bodies, Substantia Nigra.
- drug therapy : Parkinson Disease.
- chemical , metabolism : Dopamine, Nissl Bodies.
- pathology : Nissl Bodies.
- chemical , pharmacology : Neuroprotective Agents, Riluzole.
- chemical , therapeutic use : Neuroprotective Agents, Riluzole.
- Animals, Callithrix, Disease Models, Animal, Female, Immunohistochemistry, Male, Random Allocation.
Abstract
Our study aimed to determine whether riluzole, which has shown efficacy as a disease‐modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP‐induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg/kg subcutaneous) and treated with riluzole (10 mg/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH‐ and Nissl‐stained nigral neurons and of TH‐stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1272
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001026
- to stream Istex, to step Curation: 001026
- to stream Istex, to step Checkpoint: 002C65
- to stream Main, to step Merge: 006379
- to stream PascalFrancis, to step Corpus: 002853
- to stream PascalFrancis, to step Curation: 000468
- to stream PascalFrancis, to step Checkpoint: 002680
- to stream Main, to step Merge: 006719
- to stream PubMed, to step Corpus: 003C04
- to stream PubMed, to step Curation: 003C04
- to stream PubMed, to step Checkpoint: 003A10
- to stream Ncbi, to step Merge: 000647
- to stream Ncbi, to step Curation: 000647
- to stream Ncbi, to step Checkpoint: 000647
- to stream Main, to step Merge: 006159
- to stream Main, to step Curation: 004374
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence</title><author><name sortKey="Obinu, Maria C" sort="Obinu, Maria C" uniqKey="Obinu M" first="Maria C." last="Obinu">Maria C. Obinu</name></author><author><name sortKey="Reibaud, Michel" sort="Reibaud, Michel" uniqKey="Reibaud M" first="Michel" last="Reibaud">Michel Reibaud</name></author><author><name sortKey="Blanchard, Veronique" sort="Blanchard, Veronique" uniqKey="Blanchard V" first="Véronique" last="Blanchard">Véronique Blanchard</name></author><author><name sortKey="Moussaoui, Saliha" sort="Moussaoui, Saliha" uniqKey="Moussaoui S" first="Saliha" last="Moussaoui">Saliha Moussaoui</name></author><author><name sortKey="Imperato, Assunta" sort="Imperato, Assunta" uniqKey="Imperato A" first="Assunta" last="Imperato">Assunta Imperato</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E192C410F7C9A7500EF9CF5991DFCD8D876A3FF6</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.1272</idno><idno type="url">https://api.istex.fr/document/E192C410F7C9A7500EF9CF5991DFCD8D876A3FF6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001026</idno><idno type="wicri:Area/Istex/Curation">001026</idno><idno type="wicri:Area/Istex/Checkpoint">002C65</idno><idno type="wicri:doubleKey">0885-3185:2002:Obinu M:neuroprotective:effect:of</idno><idno type="wicri:Area/Main/Merge">006379</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:02-0204544</idno><idno type="wicri:Area/PascalFrancis/Corpus">002853</idno><idno type="wicri:Area/PascalFrancis/Curation">000468</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002680</idno><idno type="wicri:doubleKey">0885-3185:2002:Obinu M:neuroprotective:effect:of</idno><idno type="wicri:Area/Main/Merge">006719</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11835434</idno><idno type="wicri:Area/PubMed/Corpus">003C04</idno><idno type="wicri:Area/PubMed/Curation">003C04</idno><idno type="wicri:Area/PubMed/Checkpoint">003A10</idno><idno type="wicri:Area/Ncbi/Merge">000647</idno><idno type="wicri:Area/Ncbi/Curation">000647</idno><idno type="wicri:Area/Ncbi/Checkpoint">000647</idno><idno type="wicri:doubleKey">0885-3185:2002:Obinu M:neuroprotective:effect:of</idno><idno type="wicri:Area/Main/Merge">006159</idno><idno type="wicri:Area/Main/Curation">004374</idno><idno type="wicri:Area/Main/Exploration">004374</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence</title><author><name sortKey="Obinu, Maria C" sort="Obinu, Maria C" uniqKey="Obinu M" first="Maria C." last="Obinu">Maria C. Obinu</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion></affiliation></author><author><name sortKey="Reibaud, Michel" sort="Reibaud, Michel" uniqKey="Reibaud M" first="Michel" last="Reibaud">Michel Reibaud</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion></affiliation></author><author><name sortKey="Blanchard, Veronique" sort="Blanchard, Veronique" uniqKey="Blanchard V" first="Véronique" last="Blanchard">Véronique Blanchard</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion></affiliation></author><author><name sortKey="Moussaoui, Saliha" sort="Moussaoui, Saliha" uniqKey="Moussaoui S" first="Saliha" last="Moussaoui">Saliha Moussaoui</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion></affiliation></author><author><name sortKey="Imperato, Assunta" sort="Imperato, Assunta" uniqKey="Imperato A" first="Assunta" last="Imperato">Assunta Imperato</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Neurodegenerative Disease Program, Research Center of Paris, Aventis Pharma, S.A. Vitry sur Seine</wicri:regionArea><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion><wicri:noRegion>S.A. Vitry sur Seine</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-01">2002-01</date><biblScope unit="vol">17</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="13">13</biblScope><biblScope unit="page" to="19">19</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">E192C410F7C9A7500EF9CF5991DFCD8D876A3FF6</idno><idno type="DOI">10.1002/mds.1272</idno><idno type="ArticleID">MDS1272</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Adult animal</term><term>Animals</term><term>Behavior, Animal (drug effects)</term><term>Benzothiazole</term><term>Callithrix</term><term>Chemotherapy</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (adverse effects)</term><term>Dopaminergic neuron</term><term>Female</term><term>Immunohistochemistry</term><term>Locomotion (drug effects)</term><term>MPTP</term><term>Male</term><term>Monkey</term><term>Motricity</term><term>Neuroprotective Agents (pharmacology)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Neuroprotective agent</term><term>Nissl Bodies (drug effects)</term><term>Nissl Bodies (metabolism)</term><term>Nissl Bodies (pathology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson disease</term><term>Pathology</term><term>Prognosis</term><term>Psychotropic</term><term>Random Allocation</term><term>Riluzole</term><term>Riluzole (pharmacology)</term><term>Riluzole (therapeutic use)</term><term>Substantia Nigra (drug effects)</term><term>Treatment</term><term>locomotor impairment</term><term>neurological deficit</term><term>neuronal loss</term><term>neuroprotection</term><term>riluzole</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Dopamine Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Locomotion</term><term>Nissl Bodies</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term><term>Nissl Bodies</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Nissl Bodies</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term><term>Riluzole</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Riluzole</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Callithrix</term><term>Disease Models, Animal</term><term>Female</term><term>Immunohistochemistry</term><term>Male</term><term>Random Allocation</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Anatomopathologie</term><term>Animal adulte</term><term>Benzothiazole</term><term>Chimiothérapie</term><term>Motricité</term><term>Neurone dopaminergique</term><term>Neuroprotecteur</term><term>Parkinson maladie</term><term>Pronostic</term><term>Psychotrope</term><term>Riluzole</term><term>Singe</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our study aimed to determine whether riluzole, which has shown efficacy as a disease‐modifying agent in amyotrophic lateral sclerosis (ALS), is neuroprotective in a marmoset model of Parkinson's disease (PD). Reduction of energy demand by riluzole could be a rational neuroprotective strategy with good tolerability. The efficacy of riluzole was evaluated in marmosets by testing its ability to reduce MPTP‐induced behavioral deficits and loss of dopaminergic nigral neurons. Marmosets were divided into two groups of four animals each: animals in Group 1 were injected twice with MPTP (2 mg/kg subcutaneous) and treated with riluzole (10 mg/kg per os b.i.d.), animals in Group 2 (controls) were injected with MPTP and with the vehicle of riluzole. A third group of marmosets which did not receive MPTP or riluzole drug was introduced for neurohistopathological studies (normal animals). Marmosets treated with riluzole preserved a better motor function and neurological performance through the 26 days of assessment when compared with the controls. Histologically, there was sparing of TH‐ and Nissl‐stained nigral neurons and of TH‐stained terminals in the striatum and the putamen in the group treated with riluzole compared to the controls. We conclude that riluzole protects dopaminergic neurons and reduces behavioral deficits in a marmoset model of PD. © 2001 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Obinu, Maria C" sort="Obinu, Maria C" uniqKey="Obinu M" first="Maria C." last="Obinu">Maria C. Obinu</name></noRegion><name sortKey="Blanchard, Veronique" sort="Blanchard, Veronique" uniqKey="Blanchard V" first="Véronique" last="Blanchard">Véronique Blanchard</name><name sortKey="Imperato, Assunta" sort="Imperato, Assunta" uniqKey="Imperato A" first="Assunta" last="Imperato">Assunta Imperato</name><name sortKey="Moussaoui, Saliha" sort="Moussaoui, Saliha" uniqKey="Moussaoui S" first="Saliha" last="Moussaoui">Saliha Moussaoui</name><name sortKey="Reibaud, Michel" sort="Reibaud, Michel" uniqKey="Reibaud M" first="Michel" last="Reibaud">Michel Reibaud</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004374 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004374 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E192C410F7C9A7500EF9CF5991DFCD8D876A3FF6
|texte= Neuroprotective effect of riluzole in a primate model of Parkinson's disease: Behavioral and histological evidence
}}
| This area was generated with Dilib version V0.6.23. |  |